Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: Absolute metabolic values over 2 years during a clinical pharmacological study

American Journal of Neuroradiology

Volumn 21, Issue 7, 2000, Pages 1220-1227

  Mader, I ^a   Roser, W ^a   Kappos, L ^a   Hagberg, G ^a   Seelig, J ^a   Radue, E W ^a   Steinbrich, W ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; CHOLINE; CREATININE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; METABOLITE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REMYELINIZATION; TREATMENT OUTCOME;

ADULT; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; FEMALE; FOLLOW-UP STUDIES; GUANIDINES; HUMANS; IMAGE ENHANCEMENT; IMMUNOSUPPRESSIVE AGENTS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0033842931     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Human brain proton localized NMR spectroscopy in multiple sclerosis
2. MR proton spectroscopy in multiple sclerosis
3. Magnetic resonance spectroscopy of multiple sclerosis: In vivo detection of myelin breakdown products
4. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis
5. 1H spectroscopic imaging
6. High resolution proton NMR spectroscopy of multiple sclerosis lesions
7. Proton MRS of gadoliniumenhancing MS plaques and metabolic changes in normal-appearing white matter
8. A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging
9. Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients
10. Assessment of lesion pathology in multiple sclerosis using quantitative morphometry and magnetic resonance spectroscopy
11. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T
12. MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis
13. In vivo localized NMR proton spectroscopy of normal appearing white matter in patients with multiple sclerosis
14. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis
15. 1H Magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis
16. 1H MRSI of normal appearing white matter in multiple sclerosis
17. Benign versus secondary-progressive multiple sclerosis: The potential role of proton MR spectroscopy in defining the nature of disability
18. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis
19. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis
20. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo
21. Detection of myelin breakdown products by proton magnetic resonance spectroscopy
22. Use of magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis
23. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions
24. Chemical pathology of acute demyelinating lesions and its correlation with disability
25. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss
26. Proton MR spectroscopy and MR imaging in acute and chronic multiple sclerosis: Ringlike appearances in acute plaques
27. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: Correlative findings of active versus irreversible plaque disease
28. Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient
29. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis
30. Imaging axonal damage of normal-appearing white matter in multiple sclerosis
31. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study
32. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon-1α: Results of a preliminary study
33. 15 ± Deoxyspergualin (DSG) in the treatment of active multiple sclerosis: Final analysis of the European multicenter study
34. Defining the clinical course of multiple sclerosis: Results of an international survey
35. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
36. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
37. Selected volume excitation using stimulated echoes (VEST): Applications to spatially localized spectroscopy and imaging
38. Volume-selective multipulse spin-echo spectroscopy
39. Localized proton spectroscopy using stimulated echoes
40. Highly effective water suppression for in vivo proton NMR spectroscopy (DRYSTEAM)
41. In vivo proton spectroscopy in presence of eddy currents
42. Estimation of metabolite concentrations from localized in vivo proton NMR spectra
43. Absolute concentrations of metabolites in the adult human brain in vivo: Quantification of localized proton MR spectra
44. 1H-MR-spectroscopy
45. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference
46. Extraneous lipid contamination in single-volume proton MR spectroscopy: Phantom and human studies
47. 1H MRS of brain
48. Letter to the editor
49. Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain
50. Localized proton NMR spectroscopy in different regions of the human brain in vivo: Relaxation times and concentrations of cerebral metabolites
51. Direct absolute quantification of metabolites in the human brain with in vivo localized proton spectroscopy
52. 1H-MRS using water as internal standard
53. The concentration of N-acetyl aspartate, creatine + phosphocreatine and choline in different parts of the brain in adulthood and senium
54. Absolute quantitative proton NMR spectroscopy based on the amplitude of the local water suppression pulse: Quantification of the brain water and metabolites
55. Multiple sclerosis: Remyelination of nascent lesions
56. Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy
57. Works in progress. Measurement of proton NMR relaxation times for NAA, Cr, and Cho in acute EAE
58. N-acetyl-L-aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopy studies of the brain
59. N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development